Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07030257 · ClinicalTrials.gov registry record · Phase 1
Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
A Phase 1 study of Non-Small Cell Lung Cancer and Bladder Cancer, sponsored by Tasca Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 150
- Enrollment target
- 13
- Study locations
NCT07030257 is a Phase 1 study of Non-Small Cell Lung Cancer and Bladder Cancer that is actively recruiting participants, run by Tasca Therapeutics. The registered enrollment target is 150 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (77% lower). The trial reports 13 study locations across 11 states.
The verdict
NCT07030257, a Phase 1 study of Non-Small Cell Lung Cancer and Bladder Cancer, is actively recruiting participants, sponsored by Tasca Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 150 participants
- Enrollment target
- 13
- Study locations
Study Summary
The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of cancer in patients with advanced cancer * What medical problems do participants have when taking CP-383 Researchers will test CP-383 in all kinds of cancers at various dose levels to determine what the best dose is to study further. Researchers will also see if certain cancers that have gene mutations respond better to CP-383 Participants will: * Take CP-383 every day by mouth until the researcher learns whether CP-383 is helping slow or reduce the cancer growth * Visit the clinic weekly for the first 6 weeks for checkups and tests * Visit the clinic every 3 weeks thereafter for checkups and tests
Conditions Studied
Interventions
- DRUG CP-383
Study Locations (13)
Ohio
- Cleveland Clinic - Cleveland
- Taylor Cancer Research Center - Maumee
Texas
- NEXT Oncology - Dallas - Dallas
- START San Antonio - San Antonio
Colorado
- Sarah Cannon Research Institute at HealthONE - Denver
Florida
- Florida Cancer Specialists-Lake Nona - Orlando
Michigan
- START Midwest - Grand Rapids
Missouri
- Washington University - St Louis
Nebraska
- Nebraska Cancer Specialists - Omaha
North Carolina
- Carolina BioOncology Institute - Huntersville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2025-08-27 |
| Est. Completion | 2029-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07030257
The ClinicalTrials.gov registry entry for NCT07030257 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (77% lower). The listed sponsor is Tasca Therapeutics, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which CP-383 is the first listed.
NCT07030257 reports 13 study locations spanning 11 distinct geographic areas - top geographies include Ohio, Texas, Colorado.
Frequently Asked Questions
What is clinical trial NCT07030257 about?
NCT07030257 is a clinical study titled "Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors". The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: * Does CP-383 slow or stop the growth of cancer in patients with advanced cancer * What medical prob...
What is the current status of trial NCT07030257?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 150 participants. The study started on 2025-08-27. Estimated completion is 2029-02.
What conditions does trial NCT07030257 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Bladder Cancer, Colorectal Carcinoma, Solid Tumor Malignancies, Small Cell Lung Cancer (SCLC ).
What interventions are being tested in trial NCT07030257?
The interventions under investigation include: CP-383 (DRUG).
Who is sponsoring clinical trial NCT07030257?
This trial is sponsored by Tasca Therapeutics, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07030257 being conducted?
This trial has 13 study locations across Colorado, Florida, Michigan, Missouri, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RECRUITING · Phase 1
-
Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC
RECRUITING · Phase 1
-
A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer
RECRUITING · Phase 1
-
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
RECRUITING · Phase 1
-
A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.